Journal：Eur J Nucl Med Mol Imaging. 2017 Jan
Author：de Jong EE1, van Elmpt W2, Leijenaar RT2, Hoekstra OS3, Groen HJ4, Smit EF5,6, Boellaard R7, van der Noort V8, Troost EG2,9,10, Lambin P2, Dingemans AC11.
A total of 223 stage IV non-small cell lung cancer (NSCLC) patients were included in a phase II study (NCT01171170) randomizing between PCB treatment with or without NTG patches. For 60 participating patients, a baseline and a second [18F]FDGPET/computed tomography (CT) scan, performed between day 22 and 24 after the start of treatment, were available. Tumor response was defined as a 30 % decrease in CT and PET parameters, and was compared to RECIST response at week 6. The predictive value of these assessments for progression free survival (PFS) and overall survival (OS) was assessed with and without NTG.
Bevacizumab; Nitroglycerin; Response assessment; Stage IV NSCLC; [18F]FDG PET/CT